SentriO Oxy™ is a newly available, FDA-cleared, patent-pending breakthrough oxygenation mask system that uniquely:
 Provides ultra-high oxygenation even on low-flow (5-10 LPM) oxygen. Compared to HFNC (High Flow Nasal Cannula) at 60 LPM (liters per minute) flow, SentriO Oxy™ delivers comparable or better results using just 16% to 25% of the oxygen (86,400 liters/day of oxygen on HFNC vs. 7,200 to 14,400 liters/day on SentriO Oxy™).
 Protects and treats hypoxic COVID patients early in the infection—at HOME –to prevent multi-organ damage by only relying on an oxygen concentrator as an oxygen source. (Other devices require much higher oxygen flow than can be provided by home oxygen concentrators and in spite of high flow, some of these achieve significantly lower oxygenation).
Preventing a COVID complication is always better than reacting to one. Aside from vaccines, SentriO Oxy™ does that better than any other available therapeutic modality because nothing improves oxygenation as astoundingly effectively and as economically.
 Enables the capture of “Acute Hospital Care at Home” revenue from CMS for COVID patients, not previously available due to equipment limitation.
 Saves over 90% of cost of daily hospitalization (not possible with Pulmodyne™, Flow-Safe™, Helmet ventilator, Optiflow™, Vapotherm™ or any ventilator, which all require higher oxygen flow than can be provided at home).
 Alleviates overcrowding and exhausting burden to hospital staff. As of Sept. 2021, over 3,600 health workers have died from contracting COVID on the job. According to the Dept. of Labor, a record 589,000 quit just in the month of Sept. 2021, the 4th consecutive month of resignations above 500,000, AND the number continues to climb. 1.79 million job vacancies and growing. Every 20 “travel nurses” cost a hospital an ADDITIONAL $3 million—IF hospitals can even find them.
 Delivering better care for less at substantial savings to hospitals. Safe and simple to use device can be self-applied by a patient or an untrained family member.
 SentriO Oxy can be used in a wide range of settings from a home to a long-term care facility, to a hospital to an ICU. When used in a home setting, the oxygen source can be an oxygen generator capable of 5-10 LPM continuous flow. It generates from room air an endless amount of 93% (± 3%) oxygen.
Considering the more than 760,000 deaths in the U.S. (as of Nov. 15, 2021), the looming $8.5 trillion treatment and rehabilitation cost for post-COVID complications, the severe and costly suffering of developing nations in having to rely on tank oxygen that costs 10X as much as liquid oxygen and is difficult and unreliable to procure, it is an opportune time that the SentriO Oxy is becoming available starting late November 2021.
Consider this typical clinical scenario of oxygenation performance of HFNC compared to the SentriO Oxy™:
From both the health economics and human suffering perspectives, it is imperative that this effective device be widely adopted as expeditiously as possible. This precision device is complicated to manufacture and HealOMed is working diligently to increase production capacity in order to meet the demands for this high-value lifesaving and protective device.
It is useful not just for COVID hypoxia, but:
The SentriO Oxy™ provides patients with severe end-stage cardiopulmonary diseases a higher quality of life.